Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
P.1.17 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.126 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22750.3US
XBNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.48 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.116.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.52 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.13 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.35 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.122 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GS.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.55.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LQ.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.55NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDKNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.57NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.57NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LF.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.172NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.110NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.320NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.91NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KB.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.51.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDD.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.526 (Iota)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.621 (Mu)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used